In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in a Neutropenic Mouse Bloodstream Infection Model.

ABSTRACT:

Objectives

Rezafungin is the first new drug approved to treat candidaemia and invasive candidiasis in more than 10 years. However, data are scant on the in vivo efficacy of rezafungin and the other three approved echinocandins against different Candida auris clades.

Methods

This study involved 10 isolates representing 4 C. auris clades: South Asian (n = 2), East Asian (n = 2), South African (n = 2), and South American (n = 4, including 2 environmental isolates). In the lethality experiment and fungal tissue burden experiment (kidney, heart, and brain), cyclophosphamide-treated BALB/c male mice were intravenously infected (10⁷ and 8 × 10⁶ colony-forming units [CFU]/mouse, respectively). A 20 mg/kg dose of rezafungin was administered on days

SUBMITTER: Balazsi D 

PROVIDER: S-EPMC11433204 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature